Prevention, Early Detection and Management of Skin Cancer

A special issue of Current Oncology (ISSN 1718-7729).

Deadline for manuscript submissions: 30 June 2026 | Viewed by 1375

Special Issue Editors


E-Mail Website
Guest Editor
Department of Oncology, University of Saskatchewan, Saskatoon, SK S7N 5A2, Canada
Interests: skin cancer, prostate cancer, lung cancer, CNS cancer, epidemiology, outcome research, merkel cell carcinoma, database
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Cross Cancer Center, Department of Oncology, University of Alberta, Edmonton, AB T6G 2R3, Canada
Interests: gastrointestinal cancers; breast cancer; cutaneous malignancies; radiation related side effects; image guided radiotherapy; re-irradiation

Special Issue Information

Dear Colleagues,

This Special Issue will focus on skin cancers. We invite high-quality research addressing the following topics:

  • Updates on different pathologies of skin cancers;
  • The prevention, early detection, and management of skin cancers, with a particular focus on recent advances;
  • Rare skin cancers;
  • Genetics of skin cancers;
  • The role of cell-free DNA and liquid biopsies;
  • Immunotherapy and targeted therapies.

We welcome original articles and reviews that bridge translational research and real-world practice, particularly studies highlighting patient-centered outcomes or health disparities in skin cancer.

Prof. Dr. Patricia Tai
Dr. Kurian Joseph
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • skin cancer
  • dermato-oncology
  • cutaneous oncology
  • melanoma
  • non-melanomatous skin cancers
  • basal cell carcinoma
  • squamous cell carcinoma
  • Merkel cell carcinoma
  • sebaceous carcinoma and other adnexal carcinomas
  • prevention and detection
  • treatment
  • biomarkers
  • immunotherapy and radiotherapy
  • precision medicine
  • UV radiation
  • surgery
  • targeted therapies

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

19 pages, 777 KB  
Review
Telomerase Activity in Melanoma: Impact on Cancer Cell Proliferation Kinetics, Tumor Progression, and Clinical Therapeutic Strategies—A Scoping Review
by Omar Alqaisi, Guy Storme, Amaechi Dennis, Mohammed Dibas, Lorent Sijarina, Liburn Grabovci, Shima Al-Zghoul, Edward Yu and Patricia Tai
Curr. Oncol. 2026, 33(2), 74; https://doi.org/10.3390/curroncol33020074 - 27 Jan 2026
Viewed by 956
Abstract
Background: Melanoma outcomes have improved in recent years as a result of modern systemic therapies. A major molecular feature of melanoma is abnormal telomerase activation; this is most often caused by telomerase reverse transcriptase (TERT) promoter mutations, which occur in 50–82% of [...] Read more.
Background: Melanoma outcomes have improved in recent years as a result of modern systemic therapies. A major molecular feature of melanoma is abnormal telomerase activation; this is most often caused by telomerase reverse transcriptase (TERT) promoter mutations, which occur in 50–82% of cases and are the most common noncoding alteration in this cancer. Telomerase maintains telomere length, allowing melanoma cells to avoid senescence and continue dividing. However, how telomerase activity influences melanoma cell doubling time remains unclear, and the pathways linking TERT expression to faster cell-cycle progression require further study. Although telomerase inhibitors show promise in preclinical models, their clinical use is limited by delayed cytotoxicity and resistance. Materials and Methods: A scoping review was conducted using Scopus, ScienceDirect, MEDLINE/PubMed, and CINAHL (Cumulative Index to Nursing and Allied Health Literature). Keywords included “telomerase,” “melanoma,” “cancer,” “cell proliferation,” and “doubling time,” using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Results: Telomerase-related biomarkers were found to correlate with disease stage and survival. Suggested therapeutic strategies include enzyme inhibitors, cytotoxic nucleotide incorporation, telomere destabilization, and immunotherapies such as peptide or dendritic cell vaccines, etc. Conclusions: Understanding both telomere-dependent and -independent TERT functions is essential for developing effective biomarkers and therapies that overcome resistance and slow melanoma progression. Full article
(This article belongs to the Special Issue Prevention, Early Detection and Management of Skin Cancer)
Show Figures

Graphical abstract

Back to TopTop